Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...
While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) ...
Zacks Investment Research on MSN
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know
Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud ...
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
StemEdit encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical ...
) has been revised to $4.08 / share. This is a decrease of 20.00% from the prior estimate of $5.10 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Subscribe to Platinum Performance as of 11/29/24. Get access to powerful investment ...
Century Therapeutics Inc. Annual stock financials by MarketWatch. View the latest IPSC financial statements, income statements and financial ratios.
Organoids are an important component of translational research, particularly for evaluating drug toxicity and tissue-specific responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results